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ABSTRACT
Introduction: While most respiratory tract infections
(RTIs) will resolve without treatment, many children
will receive antibiotics and some will develop severe
symptoms requiring hospitalisation. There have been
calls for evidence to reduce uncertainty regarding the
identification of children who will and will not benefit
from antibiotics. The aim of this feasibility trial is to
test recruitment and the acceptance of a complex
behavioural intervention designed to reduce antibiotic
prescribing, and to inform how best to conduct a
larger trial.
Methods and analysis: The CHICO (Children’s
Cough) trial is a single-centre feasibility cluster
randomised controlled trial (RCT) comparing a web-
based, within-consultation, behavioural intervention
with usual care for children presenting to general
practitioner practices with RTI and acute cough.
The trial aims to recruit at least 300 children between
October 2014 and April 2015, in a single area in South
West England. Following informed consent,
demographic information will be recorded, and
symptoms and signs measured. Parents/carers of
recruited children will be followed up on a weekly basis
to establish symptom duration, resource use and cost
of the illness to the parent until the child’s cough has
resolved or up to 8 weeks, whichever occurs earlier.
A review of medical notes, including clinical history,
primary care reconsultations and hospitalisations will
be undertaken 2 months after recruitment. The trial
feasibility will be assessed by: determining
acceptability of the intervention to clinicians and
parent/carers; quantifying differential recruitment and
follow-up; determining intervention fidelity; the success
in gathering the data necessary to conduct a cost-
effectiveness analysis; and collecting data about
antibiotic prescribing rates to inform the sample size
needed for a fully powered RCT.
Ethics and dissemination: The study was approved
by the North West—Haydock Research Ethics
Committee, UK (reference number: 14/NW/1034). The
findings from this feasibility trial will be disseminated
through research conferences and peer-reviewed
journals.
Trial registration number: ISRCTN23547970.
INTRODUCTION
Children with respiratory tract infections
(RTIs) are the single most frequent user
group of primary healthcare resources, and
acute cough is the most common symptom.1
The majority of RTIs in children are self-
limiting and present a minor threat to the
child’s health. However, these cause a signiﬁ-
cant disruption to family life and are
extremely costly for service providers, parents
and employers.2 Despite evidence of their
effectiveness in self-limiting conditions,3 clin-
icians frequently prescribe antibiotics for
RTIs.4 The current scale of prescribing for
self-limiting conditions, particularly for chil-
dren, is a signiﬁcant problem for the UK’s
National Health Service (NHS) and is asso-
ciated with increased care-seeking behaviour
for minor illnesses,5 as well as antimicrobial
resistance.6 While the inappropriate use of
antibiotics and antimicrobial resistance is
now at the top of the agenda for England’s
Chief Medical Ofﬁcer and the National
Institute for Health Research (NIHR),6
primary care clinicians7 and the research
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community4 have called for the development of a sound
evidence base to reduce uncertainty around differentiat-
ing children who would beneﬁt from antibiotics from
those who would not.
Although the majority of RTI cases will resolve on
their own, a small proportion of children will develop
severe symptoms requiring hospitalisation.8 Uncertainty
regarding which children with RTIs are at risk of poor
outcome is an important driver of both prescribing
behaviour9 and parent consultations10 in primary care.
Clinicians report that they will often prescribe antibiotics
‘just in case’, if they feel uncertain about social, health
or legal outcomes.11 A perceived pressure or expectation
of antibiotics by the parents of children with RTIs has
also been cited by clinicians as a major contributing
factor towards overprescription of antibiotics.12 13
However, many parents have a no treatment preference
when they consult for an acutely unwell child.11 There is
poor agreement between parental expectation and
clinician-perceived expectations,13 and clinicians can
interpret several different parental communication
behaviours (such as asking for information at the end of
the consultation) as an expectation or pressure for anti-
biotics.12 Parents also report that they leave consultations
feeling they have insufﬁcient information about their
child’s illness.5 14 15
Changes in practice are needed to improve health out-
comes for children. This can be achieved by identifying
children for whom antibiotics are not needed, and by
providing information regarding the symptoms denoting
poor prognosis about which the parents should be vigi-
lant. Clinicians have requested clear evidence-based
information to reduce uncertainty around clinical prog-
nosis of children with RTIs to support their treatment
decisions in primary care.7 Parents have stated that they
want clear information to enable them to manage their
child’s illness.16 17 Indeed, parents of children with RTIs
are seeking information and reassurance more than anti-
biotics.10 14 Examples of such information have been
shown to reduce reconsultations18 and antibiotic use6 in
adults with RTI. If given positively, it may also improve
consultation satisfaction.19 The evidence base indicates
that the most effective interventions to reduce rates of
antibiotic prescriptions target both parents and clini-
cians during consultations20 and provide evidence-based
prescribing computer prompts.21 22
The CHICO (Children’s Cough) study is the ﬁnal
element of the TARGET Programme, which consists of
four work streams: (1) systematic reviews,11 12 21 23 24 (2)
qualitative studies,10 14 25 (3) a large cohort study involv-
ing 8394 children26 and (4) synthesising the evidence
for the generation and evaluation of a complex interven-
tion. Systematic reviews evaluated the evidence for the
effectiveness of existing interventions aimed at reducing
unnecessary antibiotic prescribing in primary care,24
natural history of RTIs in children,23 parent and clin-
ician views of antibiotic prescribing,11 and how commu-
nication within the consultation inﬂuenced treatment
decision-making.12 The qualitative studies investigated
the views, behaviours and needs of both clinicians and
parents when managing RTI in children. The cohort
study generated a clinical prediction rule to determine
which children with RTIs in primary care are more likely
to be hospitalised. Findings from across the TARGET
Programme were synthesised to develop a complex inter-
vention designed to reduce antibiotic prescribing. The
central aim of this trial is to assess the complex interven-
tion developed in the TARGET Programme, and to
understand whether it is feasible to conduct a larger
trial. The aim of the full trial would be to establish
whether a complex behavioural web-based intervention
can contribute to the reduction in overall quantity of
antibiotics prescribed and consumed, as well as improve
the consultation experience for parents/carers.
METHODS AND ANALYSIS
The CHICO trial is designed as a single-centre feasibility
practice-cluster randomised controlled trial comparing a
web-based behavioural intervention with usual care for
children presenting to primary care practices with RTI
and acute cough. The trial protocol was devised accord-
ing to the SPIRIT guidelines for randomised controlled
trials.27 The trial aims to recruit between 300 and 500
children in primary care sites between October 2014
and the end of April 2015, in a single area in South
West England.
Developing the intervention
Findings from across the TARGET Programme were
synthesised into a logic model developed using the struc-
ture of Greene and Kreuter’s Precede-Proceed model
for health promotion.28 29 Key ﬁndings from each com-
ponent of the TARGET Programme were used to high-
light the evidence for social, behavioural and
environmental factors shown to inﬂuence clinicians’
decisions to prescribe. Development of the intervention
was iterative. The parent advisory group (PAG) and clin-
ician advisory group (CAG) provided comments and
suggestions about the format of the intervention and
associated materials in the early stage and ﬁnal stage of
development. The feedback was reviewed by the team
leading the development of the intervention and modiﬁ-
cations were made where possible.
The best evidence available suggested that this should
focus on providing clinicians with accurate information
about average symptom trajectories, reducing clinical
uncertainty about complications that could lead to
hospitalisation, improve parent-clinician communication
about parent concerns, and should be followed with the
provision of individualised child-focused information.
The intervention was designed to be a tool for the
clinician to use within the child’s RTI face-to-face con-
sultation only. A web-based interface allows for a single
intervention to be delivered and comprises four
components:
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1. Structured symptom and sign collection: By using a
within-consultation web-based tool, clinicians will be
asked to record the clinical condition of the child.
2. Elicitation of parent concerns: Evidence suggests that
miscommunication between clinicians and parents
drives clinicians to prescribe antibiotics, where
requests for medication evaluations or information
are misconstrued as requests for treatment. By expli-
citly eliciting parents’ concerns, we aim to reduce the
likelihood of miscommunication.
3. A clinical prediction rule: To address the issue of the
clinician’s uncertainty about severity of the child’s
illness, we will use the clinical proﬁle of the child
using their demographic information and clinical
presentation during the consultation. The objective is
to provide an assessment of the risk that the child
will be hospitalised within 30 days postrecruitment.
4. Enhanced treatment options: We provide treatment
recommendations, highlighting no or delayed pre-
scription strategies for children with low risks of hos-
pitalisation, and a child health information booklet.
The recorded clinical condition and parent concerns
are used to produce a personalised information
booklet that explains the best home-care strategies
for each symptom, responds to parent concerns with
further information, provides information about the
natural history of common symptoms and provides
standard safety netting information. The aim of this
booklet is to not only provide more information to
parents, but also to provide clinicians with a concrete
treatment action other than prescribing.
Outcome measures
The main feasibility outcome measures will be:
▸ The acceptability of the intervention to practising
primary care clinicians and parents/carers;
▸ Recruitment at the practice and participant levels,
attrition and retention of both clinicians and partici-
pants to the trial;
▸ Parents/carers and clinicians views on the interven-
tion experience;
▸ To ascertain the levels of antibiotic prescribing in the
intervention and control groups (including CIs for
these levels) so as to inform a power calculation for a
full trial.
Additional outcomes will include trial ﬁdelity mea-
sures, and clinical and trial data collection variables to
inform the primary and secondary outcomes of the
larger trial. These will include, but are not limited to:
▸ Whether antibiotics were prescribed, either immedi-
ately or delayed, at the conclusion of the consultation
(baseline) and whether the prescribing was in line
with the intervention’s recommendations.
▸ Referrals to secondary care at the time of the consult-
ation and admission to secondary care or to the
emergency department (ED) in the 30 days
postrecruitment.
▸ Antibiotic consumption within 30 days postrecruit-
ment for both baseline consultation and any recon-
sultations; whether any antibiotics were prescribed
after consultation and prior to illness resolution.
▸ Symptom duration—time from when the child pre-
sented to primary care with cough and was recruited
to trial to when the child’s symptoms were resolved.
▸ Reconsultations (due to illness deterioration) to
primary care in the 30 days postrecruitment.
▸ Wellness as deﬁned in the CHU-9D questionnaire for
those children aged 5–11 years only; resources
required to care for children with RTI from the view-
point of the NHS, families and lost productivity, and
the completeness of this resource-use data.
▸ Use and acceptability of the intervention will be inves-
tigated by:
– Investigating frequency with which intervention is
initiated;
– Establishing the time the intervention takes and
the rate of any abandoned consultations;
– Whether clinicians revise their treatment outcome
decision (and the number of times) in the
consultation;
– Qualitative interviews with parents from the inter-
vention arm and clinicians from both arms of the
trial.
Sample size
As this is a feasibility trial, we are interested in the
recruitment rate in the intervention and control groups
to inform the design of a larger main trial. We will
monitor differential recruitment to inform whether a
1:1 recruitment strategy should be used for the full trial,
and whether we need to provide more training/clarity
to general practitioners (GPs) regarding the inclusion
and exclusion criteria.
Recruitment rates from the TARGET cohort study,
using Bristol practices between October and April,
suggest around 10 patients per practice were recruited
(mean=11.2 (95% CI 8.9 to 13.5)). To ensure we will
have sufﬁcient participants for our process measures, at
least 15 practices per arm of the trial will be recruited
and randomised. This number of practices takes into
consideration the large variability we have previously
observed in recruitment between practices and the
potential to assess differential recruitment between the
arms of the trial. Practices will be expected to recruit at
least 10 participants per practice in 7 months, enabling
a minimum of 300 children to enter the (feasibility)
trial. This should be sufﬁcient to calculate sufﬁciently
precise estimates of the feasibility outcomes listed above.
Practice recruitment
General practices will be invited to participate in the
trial from locations in Bristol and the surrounding areas
via the local primary care Clinical Research Network
(CRN). The recruiting clinicians will attempt to recruit
all eligible patients during the 7-month recruitment
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period. Recruiting clinicians will record online if partici-
pants declined to participate or were missed and the
reasons for these labelled as ‘patient not recruited’.
A large geographical area of practices will be invited
to participate to avoid saturation of research studies in
some practices, and to maximise the generalisability of
the sample of children.
Randomisation process
The randomisation process will be a one-off randomisa-
tion of each recruited primary care site (general prac-
tice) occurring before the start of study recruitment.
Given that general practice consultation and antibiotic
prescribing rates tend to be higher in some areas than
others, the randomisation process will be stratiﬁed to
achieve balance with respect to: total number of children
in the age range registered at the practice (list size); and
proportion of children’s amoxicillin antibiotic prescrip-
tions per child in the practice, as a proxy measure of anti-
biotic prescribing for the practice (prescribing rate).
Owing to the nature of the intervention delivery, it will
not be possible to blind practices to their allocation to
either control or intervention group. Nevertheless, the
explanation prior to randomisation emphasises optimis-
ing RTI management rather than reducing antibiotic
prescribing, and is the same for both groups. At the indi-
vidual level, the parents will be invited to participate in
the feasibility study knowing this is a trial testing two
approaches to RTI management, but will not be aware
whether they are in the intervention or control arm.
Furthermore, the research staff reviewing participants’
primary care medical record, assessing outcomes and
conducting the analysis will not know to which group
participants were allocated. Balance across the arms for
individual characteristics will be monitored carefully by
the Data Monitoring Committee (DMC) to ensure
differential recruitment is minimised as much as pos-
sible. In order to minimise bias in the trial30 and in data
collection, trial processes were reviewed prior to the
start of practice and participant recruitment to assess
internal and external validity measures. Processes have
been put in place speciﬁcally to tackle the known issue
of selection bias in cluster trials such as emphasising
that clinicians recruit all eligible children and requesting
that they systematically record reasons for not recruiting
children.30
Participant recruitment
Practices will publicise the study in a number of ways—for
example, on the practice website or in their newsletter.
Families telephoning for an appointment and attending
primary care sites with their potentially eligible children
will be invited to participate in the trial either by the
reception staff or by their clinicians. Eligibility will be
checked and informed consent will be obtained for parti-
cipants from the parent or legal guardian presenting to
both intervention and control group practices.
Participants have at least 24 h to decide if they wish to
participate as this will be checked at the ﬁrst follow-up
contact. Participants will leave the consultation with an
information pack containing the participant information
sheet, copy of their consent form, and follow-up question-
naire. No incentives will be provided to encourage parti-
cipants to enter the study. A £5 shopping voucher will be
provided to families by way of a ‘thank you’ for comple-
tion of the follow-up data collection.
Participants
Children will be included if they are between 3 months
and 12 years of age, and present with a RTI with cough
of no more than 28 days duration prior to consultation.
They will be eligible if they present with illnesses such as
asthma, epilepsy or diabetes, and RTI, including infect-
ive exacerbation of asthma, as well as children who
require same day hospital assessment or admission.
Children will be excluded if they: present with acute,
non-infective exacerbation of asthma; present with RTI
without cough or cough of more than 28 days; are
considered to have a high risk of serious infection
(eg, immunocompromised, cystic ﬁbrosis, splenectomy);
are temporarily registered with the NHS primary care
site (general practice, walk-in centre, GP out of hours
centre or polyclinic) and are likely to be unregistered/
non-resident within a month; have parent/carers who
are unable or unwilling to assist with the study; are
already recruited to the CHICO trial.
Data collection
Baseline data will be collected from the participants and
parents/carers by both control and intervention clini-
cians during a routine clinical consultation. The clini-
cians will enter the child’s demographic characteristics,
carer-reported symptoms, clinician-measured signs and
clinical outcomes of the consultation onto a secure web-
based database. The intervention group will also have
the facilities to record parental concerns on the web-
based database. Information about user interaction with
the web-based system will be collected for control and
intervention versions of the site. Exposure to the site will
be assessed by measuring the number of times the clini-
cians use the web-based intervention and the amount of
time spent on each page of the site.
Follow-up data will be collected from parents/carers
weekly (by phone or online) until the child’s symptoms
are resolved, or for 8 weeks if the parent informs the
team that the cough has not resolved. The information
collected will include whether the child’s symptoms have
resolved, antibiotic consumption, any further contact
with health professionals, quality of life data, relevant
out-of-pocket expenditure and associated time off work.
The aim of the health economics component of the
study will be to inform the design of a full economic
evaluation alongside the larger trial for assessing the
intervention in terms of value for money.
Parents/carers in the intervention group and clini-
cians from both groups will be invited to participate in
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semistructured interviews to explore their views, experi-
ences and acceptability of the intervention. Interviews
with parents/carers will be conducted either in the week
following recruitment (in order to facilitate recall of the
consultation experience) or after their child has recov-
ered to reﬂect on the whole follow-up data collection
process. Purposive sampling will be used to include a
maximum variation sample of parents/carers, including
those with a range of ages of children and ethnicity; par-
ticipants will be selected from areas of high and low
social-economic deprivation, and with a range of illness
severity scores and treatment outcomes. We will inter-
view one clinician from each participating practice and
up to 30 parents/carers in total to explore views and
experiences of the intervention. These interviews will
help us gain understanding of the barriers and facilita-
tors of the intervention implementation to inform the
design of a future, larger trial. Clinicians who agree to
participate in interviews will be reimbursed ﬁnancially
for their time. A £5 shopping voucher will be provided
to families as a ‘thank you’ for participating in the
interviews.
We will conduct a primary care medical record review
at the recruiting practices to collect data relating to the
30 days following the recruitment consultation. This will
include information about the time taken for the
recruiting consultation, and RTI-related antibiotic pre-
scriptions, reconsultations and hospitalisations. The
medical record review will also record consultations and
related antibiotic prescriptions for RTI in the year prior
to recruitment. The review will be completed by a
member of the research team who will be trained in the
medical notes system for the practice. All data will be
recorded on the secure web-based database and anon-
ymised. These data can also be used to verify the data
collected by the clinicians at recruitment and reported
by the parent/carers at the follow-up and this will help
to inform whether the medical record review is a robust
mechanism for the larger trial.
Data analysis procedure
The main statistical analyses will be carried out accord-
ing to the study analysis plan. Descriptive statistics
(means, SDs and non-parametric measures, where
appropriate) will be used to describe the characteristics
of the parents/carers, children and recruiting clinicians
from the control and intervention group practices. To
help address our outcomes, we will: (1) investigate the
post-test probability of hospitalisation thresholds at
which different clinicians choose to prescribe immediate
or delayed antibiotics; (2) scrutinise between-group
differences in prescribing rates and calculate 95% CIs to
inform the sample size of a larger trial; (3) scrutinise
antibiotic prescribing rates postconsultation in both
arms to offset transference of prescribing at a later date;
(4) collect information on reconsultations, ED visits and
hospitalisations during follow-up from the parents,
which will be compared with the information collected
at the medical record review to assess whether this latter
method will be robust enough for the larger trial; (5)
estimate the intraclass correlations by practice of the
outcome measurements (although we appreciate the
small number of practices will limit our conclusions);
(6) study the variability of the size of clusters from each
practice to help inform the inﬂation factor for our
sample size; (7) conduct intervention group logistic
regression to look at differences in parental concerns
about hospitalisation between the very low-risk group and
the normal-risk and high-risk groups, which will help
inform whether we have comprehensively addressed all
concerns and weighted the advice accordingly. All quanti-
tative data will be analysed using Stata V.12.0.
Interviews will be transcribed and anonymised.
Analysis of qualitative data will begin shortly after data
collection starts, and will be ongoing and iterative.
Analysis will inform further data collection, and the ana-
lytic insights from data gathered in earlier interviews will
help identify any changes that need to be made to the
topic guides during later interviews. Qualitative analysis
of the transcripts will follow recognised thematic analysis
procedures using NVivo software. Thematic analysis, uti-
lising a data-driven inductive approach, will be used to
scrutinise the data in order to identify and analyse pat-
terns and themes of particular salience for participants
and across the data set. Transcripts will be coded and
global themes developed from the codes. Two research-
ers will code the transcripts, and any differences will be
discussed and resolved within the research team in
order to achieve a coding consensus and to ensure
robust analysis.
Health economic analysis will be exploratory. We will
provide descriptive statistics on resource use and cost by
category of resource and by randomisation group in
order to identify important cost drivers. We will also
investigate the level and nature of missing data to assess
the methods of data collection and inform how best to
carry this out in the larger trial. We will review the
appropriateness of different outcomes with which to
compare costs.
The ﬁdelity measures will be explored to respond to
the detailed plans for the intervention content and
implementation. This will be achieved by constructing
an ‘intervention map’ that will specify all the behav-
ioural components that we wish to change. Where pos-
sible, parallel process measures will be developed to
establish the extent to which processes or outcomes
have been modiﬁed. These are likely to include mea-
sures for: (1) adherence to the intervention delivery,
(2) exposure to the intervention, assessed by measur-
ing the number of times the clinicians use the web-
based intervention, the amount of time spent reading
the background information as well as an assessment
of the quality of the intervention delivered, and (3)
differentiation between intervention and control
groups in terms of recruitment levels, attrition rates
and disease severity.
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Patient and public involvement
This proposal has been developed collaboratively with
our PAG, and their comments and suggestions about the
format of the intervention and parent/carer materials
have informed for both the intervention and the ﬁnal
design of the feasibility study. The PAG will meet
throughout the study, twice per year, allowing the investi-
gators to report on progress of the study and discuss
issues that arise during the study. PAG members will
input in all the material for parents/carers as and when
these are developed, including the patient information
sheet, intervention materials and the topic guide for
interviews. We have also formed a CAG, involving GPs
and practice nurses, to assist with developing and reﬁn-
ing the intervention. They will meet once in person and
then contribute by Skype or email to reﬁne GP/nurse
information and intervention delivery. We will work
closely with our advisory groups, particularly during the
ﬁrst 9 months of this work package.
ETHICS AND DISSEMINATION
Burden
As the feasibility trial is assessing a behavioural interven-
tion and participants are attending for a routine consult-
ation with a clinician, there are no risks to the
participants taking part in this study. Children will not be
randomised to receive a medication or intervention, and
no treatment will be withheld. Further clinical manage-
ment will be decided on by the patient’s clinician, as it is
the choice of the recruiting clinician as to whether the
participants are treated or not for their cough.
The main burden will be the additional time asso-
ciated with participating in the study. This has been
reduced to a minimum by only asking some short
concise questions during their routine consultation, and
questions about the child’s recovery, treatment and
healthcare resources at follow-up.
The intervention itself will be assessed as to whether
the components of the intervention could potentially
increase hospitalisations by virtue of reducing antibiotic
prescribing, and so families will be asked weekly whether
their child has been hospitalised in the preceding 7 days
via the weekly phone call.
Adverse events and serious adverse events
Any unexpected adverse events (AEs) deﬁned as ‘any
untoward medical occurrence in a trial participant’ and
serious AEs (SAEs)—deﬁned below—will be monitored
by the trial team and reviewed at monthly management
group meetings.
From our earlier work, we anticipate that approxi-
mately 1% (2–4 children) of children presenting with
RTI will be hospitalised. We will ask recruiting practices
to inform the trial coordinator of any unexpected SAEs
that occur during the child’s participation in the trial.
The principal investigator and trial coordinator will
assess the nature of the SAE for seriousness, causality and
expectedness. Following the initial report, follow-up data
may be requested by the trial coordinator. All reports will
be submitted to the DMC for scrutiny of our ongoing
ﬁndings. Where the SAE is both related and unexpected,
the trial coordinator will notify the main REC, the
sponsor of the trial, and its research governance ofﬁce
within 15 days of receiving notiﬁcation of the SAE.
As one of the outcomes for the trial is hospitalisation,
we do expect some participants to be admitted to hos-
pital due to a deterioration of their underlying illness,
for example, pneumonia, empyema and deteriorating
bronchiolitis. At follow-up, parents/carers will be rou-
tinely asked if they have reconsulted for their child’s
illness and if so, where this was done. In addition,
whether the child has been hospitalised will also be
asked. Once a child has been identiﬁed as hospitalised,
either in the ED or on a ward, the standard SAE process
will be followed as described above. All expected SAEs
will be reported as part of the outcome to the trial.
Definition of a SAE
This is any untoward and unexpected medical occur-
rence or effect that: results in death; is life-threatening
(refers to an event during which the participant was at
risk of death at the time of the event, and not to an
event that might have caused death had it been more
severe in nature); requires hospitalisation or prolonga-
tion of existing hospitalisation; or results in persistent/
signiﬁcant disability or incapacity.
Study sponsorship
The University of Bristol will act as sponsor for study.
Delegated responsibilities will be assigned to the
Universities and NHS trusts taking part in this study. The
study is open to inspection and audit by the University
of Bristol under its remit as sponsor.
Dissemination
The outputs from this research will comply with the
TARGET Programme’s publication policy. All results will
be described in the Programme’s ﬁnal report and as
papers in peer-reviewed journals. Papers will be produced
to describe the ﬁndings from this feasibility study, and
results will be presented at national and international
research conferences. A summary of the ﬁndings will be
sent to participating practices (and this will be available
to their patients) on completion of the CHICO study.
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